100
Participants
Start Date
March 5, 2024
Primary Completion Date
July 23, 2026
Study Completion Date
January 23, 2031
FPI-2265
"Investigational treatment FPI2265 is a PSMA ligand radiolabelled with 225Ac.~Other Names:~225Ac-PSMA-I\&T"
RECRUITING
Laura and Isaac Perlmutter Cancer Center at NYU Langone, New York
RECRUITING
Memorial Sloan Kettering Cancer Center - NYC, New York
ACTIVE_NOT_RECRUITING
United Theranostics, Glen Burnie
RECRUITING
Biogenix Molecular, LLC, Miami
RECRUITING
BAMF Health, Grand Rapids
RECRUITING
University of Iowa Hospitals and Clinics, Iowa City
RECRUITING
SSM Health Saint Louis University Hospital, St Louis
RECRUITING
XCancer, Omaha
RECRUITING
VA North Texas Health Care System, Nuclear Medicine Service, Dallas
RECRUITING
The University of Texas Southwestern Medical Center, Dallas
RECRUITING
U.T. MD Anderson Cancer Center, Houston
RECRUITING
New Mexico Oncology Hematology Consultants Ltd., Albuquerque
RECRUITING
VA Greater Los Angeles Healthcare System, Los Angeles
RECRUITING
University of California Los Angeles, Los Angeles
RECRUITING
City of Hope Comprehensive Cancer Center, Duarte
RECRUITING
Hoag Health Center Irvine, Irvine
RECRUITING
UCSF School of Medicine, San Francisco
RECRUITING
Oregon Health and Science University (OHSU, Knight Cancer Center), Portland
Lead Sponsor
Fusion Pharmaceuticals Inc.
INDUSTRY